Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial
- Jeongkuk Seo
- , Won Seog Kim
- , Jin Seok Kim
- , Seok Jin Kim
- , Jae Hoon Lee
- , Jun Shik Hong
- , Gyeong Won Lee
- , Sung Yong Oh
- , Ji Hyun Lee
- , Dok Hyun Yoon
- , Won Sik Lee
- , Hyo Jung Kim
- , Jae Yong Kwak
- , Hye Jin Kang
- , Jae Cheol Jo
- , Yong Park
- , Ho Sup Lee
- , Hyo Jin Kim
- , Cheolwon Suh*
*Corresponding author for this work
- Dong-A University
- Sungkyunkwan University
- Yonsei University
- Gachon University
- Gyeongsang National University
- University of Ulsan
- Inje University
- Hallym University
- Korea Institute of Radiological and Medical Sciences
- Korea University
- Kosin University
Research output: Contribution to journal › Journal article › peer-review
15
Link opens in a new tab
Scopus
citations